Search Results - "Fabbri, L.M."

Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update by Fabbri, L M, Hurd, S S

Get full text

Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients by Maestrelli, P, Paska, C, Saetta, M, Turato, G, Nowicki, Y, Monti, S, Formichi, B, Miniati, M, Fabbri, L.M

“…Oxidant/antioxidant imbalance is implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). The current study examined the expression of…”
Get full text

CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer by Miotto, D, Cascio, N. Lo, Stendardo, M, Querzoli, P, Pedriali, M, De Rosa, E, Fabbri, L.M, Mapp, C.E, Boschetto, P

“…Abstract The dual role of tumour-infiltrating macrophages and lymphocytes on nonsmall cell lung cancer (NSCLC) progression and prognosis may be due to the…”
Get full text

Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections by Richeldi, L, Mariani, M, Losi, M, Maselli, F, Corbetta, L, Buonsanti, C, Colonna, M, Sinigaglia, F, Panina-Bordignon, P, Fabbri, L.M

“…The triggering receptor expressed on myeloid cells (TREM)-1 is a recently described molecule, which plays an important role in myeloid cell-activated…”
Get full text

Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis by Miotto, D, Ruggieri, M.P, Boschetto, P, Cavallesco, G, Papi, A, Bononi, I, Piola, C, Murer, B, Fabbri, L.M, Mapp, C.E

“…The aim of this study was to determine whether the T-helper 2-type cytokines interleukin (IL)-13 and -4 are involved in mucus hypersecretion, the hallmark of…”
Get full text

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis by Luppi, F., Cerri, S., Beghè, B., Fabbri, L.M., Richeldi, L.

“…Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis…”
Get full text

Predominant emphysema phenotype in chronic obstructive pulmonary disease patients by Boschetto, P, Miniati, M, Miotto, D, Braccioni, F, De Rosa, E, Bononi, I, Papi, A, Saetta, M, Fabbri, L.M, Mapp, C.E

“…Patients with fixed airflow limitation are grouped under the heading of chronic obstructive pulmonary disease (COPD). The authors investigated whether COPD…”
Get full text

Macrolides in the treatment of asthma and cystic fibrosis by Ferrara, G., Losi, M., Franco, F., Corbetta, L., Fabbri, L.M., Richeldi, L.

“…Asthma and cystic fibrosis are two respiratory diseases characterized by chronic inflammation, leading to remodelling of the airways. Macrolides are widely…”
Get full text

CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer by Miotto, D, Boschetto, P, Bononi, I, Milani, G, Legorini, C, Cavallesco, G, Lo Cascio, N, Zeni, E, Fabbri, L.M, Mapp, C.E

“…Summary Non-small cell lung cancer (NSCLC) shows a particular aggressive behaviour. Tumour associated macrophages (TAMs) play an important role in tumour…”
Get full text

Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis by Miotto, D, Boschetto, P, Bononi, I, Zeni, E, Cavallesco, G, Fabbri, L.M, Mapp, C.E

“…Vasoactive intestinal peptide (VIP) is a neuropeptide involved in the regulation of airway mucus secretion. The biological functions of VIP are mediated…”
Get full text

Malattie croniche da ricercare attivamente e mettere in trattamento nel paziente anziano multimorbido al momento della dimissione da un reparto di Medicina Interna a seguito di un ricovero per insufficienza respiratoria acuta attribuita a riacutizzazione di BPCO by Fabbri, Guest Editors: L.M., Nozzoli, C.

“…IntroduzioneP. Gnerre, L.M. Fabbri, C. Nozzoli Criteri minimi per la diagnosi, valutazione di gravità e trattamento dello scompenso cardiacoP. Gnerre BPCO e…”
Get full text

In memoriam Prof. Hisamichi Aizawa, 1950–2011: Figure 1 by Fabbri, L.M., O'Byrne, P.M.

Get full text

Roflumilast with long-acting β 2 -agonists for COPD: influence of exacerbation history by Bateman, E.D., Rabe, K.F., Calverley, P.M.A., Goehring, U.M., Brose, M., Bredenbröker, D., Fabbri, L.M.

“…The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations and improves lung function in patients with severe-to-very severe…”
Get full text

Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma by Papi, A, Paggiaro, P, Nicolini, G, Vignola, A.M, Fabbri, L.M

“…Recommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta₂-agonist. The present study was…”
Get full text

small airways and distal lung compartment in asthma and COPD: a time for reappraisal by Contoli, M, Bousquet, J, Fabbri, L.M, Magnussen, H, Rabe, K.F, Siafakas, N.M, Hamid, Q, Kraft, M

“…To cite this article: Contoli M, Bousquet J, Fabbri LM, Magnussen H, Rabe KF, Siafakas NM, Hamid Q, Kraft M. The small airways and distal lung compartment in…”
Get full text

Efficacy of standard rehabilitation in COPD outpatients with comorbidities by CRISAFULLI, E, GORGONE, P, OLIVIERI, D, FABBRI, L. M, CLINI, E. M, VAGAGGINI, B, PAGANI, M, ROSSI, G, COSTA, F, GUARRIELLO, V, PAGGIARO, P, CHETTA, A, DE BLASIO, F

“…A prospective study was performed to confirm the prevalence pattern of the most frequent co-morbidities and to evaluate whether characteristics of patients,…”
Get full text

Prioritised research agenda for prevention and control of chronic respiratory diseases by Bousquet, J, Kiley, J, Bateman, E D, Viegi, G, Cruz, A A, Khaltaev, N, Aït Khaled, N, Baena-Cagnani, C E, Barreto, M L, Billo, N, Canonica, G W, Carlsen, K-H, Chavannes, N, Chuchalin, A, Drazen, J, Fabbri, L M, Gerbase, M W, Humbert, M, Joos, G, Masjedi, M R, Makino, S, Rabe, K, To, T, Zhi, L

“…The 2008-2013 World Health Organization (WHO) action plan on noncommunicable diseases (NCDs) includes chronic respiratory diseases as one of its four…”
Get full text

Serum-mediated relaxant response to toluene diisocyanate (TDI) in isolated guinea-pig bronchi by BOSCHETTO, P, JOVINE, L, CHITANO, P, DE MARZO, N, PLEBANI, M, FAGGIAN, D, FABBRI, L.M, MAPP, C.E

“…The present study was designed to evaluate whether pre-incubation with serum, obtained from both control and toluene diisocyanate (TDI)-immunized guinea-pigs,…”
Get full text

Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease by Beghé, B, Hall, I.P, Parker, S.G, Moffatt, M.F, Wardlaw, A, Connolly, M.J, Fabbri, L.M, Ruse, C, Sayers, I

“…To cite this article: Beghé B, Hall IP, Parker SG, Moffatt MF, Wardlaw A, Connolly MJ, Fabbri LM, Ruse C, Sayers I. Polymorphisms in IL13 pathway genes in…”
Get full text

Regular vs prn nebulized treatment in wheeze preschool children by Papi, A, Nicolini, G, Baraldi, E, Boner, A.L, Cutrera, R, Rossi, G.A, Fabbri, L.M

“…International guidelines recommend regular treatment with inhaled glucocorticoids for children with frequent wheezing; however, prn inhaled bronchodilator…”
Get full text